Empirical Treatment of Pneumonia

Introduction to Pneumonia Treatment

• The American Thoracic Society recommends empirical antibiotic treatment for pneumonia to be stratified by severity and setting, with outpatients receiving oral monotherapy and hospitalized patients requiring combination therapy 1, 2

Outpatient/Ambulatory Treatment

• For outpatients with mild community-acquired pneumonia, the Infectious Diseases Society of America recommends treatment options including aminopenicillin, macrolide monotherapy, doxycycline, or respiratory fluoroquinolone, depending on the region's resistance patterns 1, 2, 3
• In areas with high macrolide resistance, a β-lactam/macrolide combination or respiratory fluoroquinolone is recommended even for outpatients 2

Hospitalized Non-ICU Patients

• The Infectious Diseases Society of America recommends combination therapy with a β-lactam plus macrolide for hospitalized non-ICU patients, which has strong evidence for reducing mortality 1, 2
• Recommended regimens include ceftriaxone or cefotaxime plus azithromycin or clarithromycin, ampicillin-sulbactam plus macrolide, or piperacillin-tazobactam plus macrolide 1, 2, 4

ICU/Severe Community-Acquired Pneumonia

• For patients with severe pneumonia, the American Thoracic Society recommends immediate broad-spectrum combination therapy to reduce mortality 1, 2
• For patients without Pseudomonas risk factors, recommended regimens include non-antipseudomonal cephalosporin III plus macrolide or respiratory fluoroquinolone plus cephalosporin III 1, 2, 5

Hospital-Acquired Pneumonia

• The Infectious Diseases Society of America recommends treatment for hospital-acquired pneumonia to be guided by local antibiograms and stratified by mortality risk and MRSA risk factors 6, 7
• For low mortality risk patients without MRSA risk factors, monotherapy with piperacillin-tazobactam, cefepime, levofloxacin, imipenem, or meropenem is recommended 6, 7

Aspiration Pneumonia

• For aspiration pneumonia, the Infectious Diseases Society of America recommends treatment with β-lactam/β-lactamase inhibitor, clindamycin, or IV cephalosporin plus oral metronidazole for hospital ward patients, and clindamycin plus cephalosporin for ICU or nursing home patients 5, 8

Duration and Route of Therapy

• The American Thoracic Society recommends treatment duration to generally not exceed 8 days in responding patients, with oral therapy possible from the beginning in ambulatory pneumonia and switch from IV to oral when clinically stable 1, 4, 5

Critical Timing Considerations

• The Infectious Diseases Society of America recommends antibiotic treatment to be initiated immediately after diagnosis, particularly in patients with sepsis, and the first antibiotic dose to be administered while still in the emergency department 1, 2, 4